Pseudomonas aeruginosa diversity in distinct paediatric patient groups

G A Tramper-Stranders1, C K van der Ent, T F W Wolfs

  • 1Department of Paediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands. g.tramper@umcutrecht.nl

Insights

Clonal Pseudomonas aeruginosa isolates primarily infect cystic fibrosis (CF) patients and are not found in other pediatric groups. This study highlights the limited transmission of these specific CF pathogen clones.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Genetics

Background:

  • Pseudomonas aeruginosa is a significant opportunistic pathogen, particularly in immunocompromised individuals and those with compromised host defenses.
  • Cystic fibrosis (CF) patients are known to harbor specific clonal isolates of P. aeruginosa, but their presence in other patient populations remains unclear.
  • Understanding the diversity and clonality of P. aeruginosa is crucial for infection control and treatment strategies.

Purpose of the Study:

  • To investigate the genotypic diversity and clonal structure of Pseudomonas aeruginosa isolates across five distinct pediatric patient groups.
  • To determine if clonal P. aeruginosa isolates found in cystic fibrosis patients also infect non-CF patient groups.
  • To assess the prevalence and transmission patterns of P. aeruginosa clones in susceptible pediatric populations.

Main Methods:

  • Culturing and phenotypic characterization of P. aeruginosa isolates from 157 pediatric patients across five groups: CF (first infection and chronic), urinary tract infection, chronic suppurative otitis media, and intensive-care/immunodeficiency.
  • Antimicrobial resistance testing and molecular typing using pulsed-field gel electrophoresis (PFGE) for genetic relatedness.
  • Calculation of Simpson's diversity index to quantify genotypic diversity within each patient group.

Main Results:

  • CF-chronic patients exhibited the highest number of distinct P. aeruginosa phenotypes and genotypes.
  • Isolates from the CF-chronic group showed significantly lower diversity compared to other patient groups.
  • Clonal P. aeruginosa isolates were identified in CF patients (both first infection and chronic groups) but not in the other three non-CF pediatric groups.
  • No characteristic antimicrobial resistance patterns were associated with specific patient groups or clonal isolates.

Conclusions:

  • Pseudomonas aeruginosa isolates from chronically infected CF patients display reduced genotypic diversity.
  • Clonal P. aeruginosa isolates are specific to cystic fibrosis patient cohorts and do not appear to transmit to non-CF pediatric patient groups.
  • The study did not observe the transmission of clonal CF isolates to other investigated patient populations, suggesting distinct epidemiological patterns.

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...